Ottawa, Canada, January 2, 2014 – Pharmaceutical Technology recently interviewed Sussex Research scientists, including Dr. Brady Clark, on the role of Nuclear Magnetic Resonance Spectroscopy (NMR) and Mass Spectrometry (MS) in Glycan Synthesis and Analysis. Sussex Research is a well known specialist in carbohydrate synthesis and glycodesign with an established international reputation. As discussed in the interview, NMR and MS are vital to successful development of glycosylation in syntheses of carbohydrate-based molecules and glycans. While NMR analysis provides crucial structural information of synthesized glycans that cannot be determined in any other way, MS analysis confirms molecular weight of target synthons. In bioanalytical analyses, LC-MS/MS is ideal for quantitation of free sugars in biological matrices.
To read the full article, you are directed to PharmaTech.com (http://www.pharmtech.com/role-nmr-and-mass-spectroscopy-glycan-analysis).
About Sussex Research: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.
SHARE THIS ARTICLE ON:
Get product updates and announcements from Sussex Research in your inbox at no charge.
Sussex Research Laboratories Inc. to Exhibit at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics
May 4, 2022
Sussex Research Laboratories Inc. to Exhibit at The American Peptide Symposium 2022 - "Peptide Science at the Summit"
April 26, 2022
Sussex Research Laboratories Inc. / Queen’s University collaboration receives support to develop novel small molecule therapies for COVID-19
May 21, 2020
Sussex Research Laboratories Inc. / Queen’s University collaboration receives Collaborative Research and Development Grant (CRDPJ) to develop synthetic strategies toward Deuterium-labeled pharmaceutical compounds with improved efficacy.
August 22, 2018
Sussex Research Laboratories Inc. acquires Chemaphor Chemical Services from Avivagen
October 13, 2017